High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial
International Journal of Radiation Oncology*Biology*Physics · 2023-04 · 115 (5) · 1129-1137
DOI: 10.1016/j.ijrobp.2022.11.006 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023-04. Verfasst von Jing You und 19 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Canc…. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
PURPOSE: The standard dose (SD) of definitive concurrent chemoradiotherapy (dCRT) remains 50.4 Gy in patients with esophageal cancer; a higher dose, when applied with conventional radiation therapy techniques, increases toxicities without improving survival. We investigated whether a high dose of 59.4 Gy using intensity-modulated radiation therapy (IMRT) would improve survival without increasing toxicities. METHODS: Patients with inoperable thoracic esophageal squamous cell carcinoma (SCC) referred for dCRT were randomly assigned (1:1) to high-dose (HD) IMRT (59.4 Gy) or SD IMRT (50.4 Gy). Chemotherapy consisted of 6 cycles of concurrent weekly paclitaxel and carboplatin and a maximum of 2 cycles of consolidation chemotherapy. Nutritional intervention was implemented for patients with malnutrition on the basis of nutritional screening. The primary endpoint was median overall survival (mOS). Analyses were by modified intention to treat. RESULTS: Between April 30, 2016, and April 30, 2019, 167 patients were enrolled at 9 participating centers in China. Seventy-one patients in the HD and 73 patients in the SD groups were included in the analysis; 86.8% of the patients completed radiation therapy and 70.1% received 5 or 6 cycles of concurrent chemotherapy. The median follow-up was 36.0 months. The mOS was 28.1 and 26.0 months in the HD and SD arms, respectively (P = .54). A total of 7 treatment-related deaths were observed. Grade 3 or worse treatment-related toxicities were observed in 62% and 68.5% of the patients in the HD and SD arms, respectively (P = .675). CONCLUSIONS: For patients with inoperable thoracic esophageal SCC, a dose of 59.4 Gy did not improve survival compared with the SD of dCRT using IMRT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
- Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
- College of Clinical Medicine for Oncology, Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- Department of Radiation Oncology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Chin…
- Department 1st Radiation Therapy, Anyang Tumor Hospital, Anyang, China.
- Chest Radiotherapy Ward 2, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
Zitieren
APA
You, J., Zhu, S., Li, J., Li, J., Shen, J., Zhao, Y., Li, X., Jia, L., Li, Q., Yang, J., Wu, Y., Shen, W., Wu, H., Wu, X., Wang, X., Ren, Y., He, J., Lin, P., Zhu, G., & Shi, A. (2023). High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial. International Journal of Radiation Oncology*Biology*Physics, 115(5), 1129-1137. https://doi.org/10.1016/j.ijrobp.2022.11.006
Vancouver
You J, Zhu S, Li J, Li J, Shen J, Zhao Y, et al. High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial. International Journal of Radiation Oncology*Biology*Physics. 2023;115(5):1129-1137. doi:10.1016/j.ijrobp.2022.11.006
BibTeX
@article{You2023,
author = {You, Jing and Zhu, Shuchai and Li, Jiancheng and Li, Jie and Shen, Junyue and Zhao, Yidian and Li, Xiaomin and Jia, Lin and Li, Qingshan and Yang, Jun and Wu, Yiqun and Shen, Wenbin and Wu, Haishan and Wu, Xueqin and Wang, Xiaomin and Ren, Yaqiong and He, Jun and Lin, Pingping and Zhu, Guangying and Shi, Anhui},
title = {High-Dose Versus Standard-Dose Intensity-Modulated Radiotherapy With Concurrent Paclitaxel Plus Carboplatin for Patients With Thoracic Esophageal Squamous Cell Carcinoma: A Randomized, Multicenter, Open-Label, Phase 3 Superiority Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2023},
volume = {115},
number = {5},
pages = {1129--1137},
doi = {10.1016/j.ijrobp.2022.11.006}
}
EUVIMED